Company Overview of Putney, Inc.
Putney, Inc., a pet pharmaceutical company, develops and sells generic prescription medicines for pets. It provides veterinary-approved products, such as Enrofloxacin flavored tablets for use in dogs and cats for the management of diseases associated with bacteria susceptible to Enrofloxacin; Cefpodoxime Proxetil tablets to dogs for the treatment of skin infections (wounds and abscesses); Mupirocin ointment for the topical treatment of canine bacterial infections of the skin; Carprofen caplets to dogs for pain associated with canine osteoarthritis, and for controlling post-operative pain from certain surgeries; and Ketamine HCl for Injection C-III, a nonnarcotic nonbarbiturate agent for anes...
One Monument Square
Portland, ME 04101
Founded in 2006
Key Executives for Putney, Inc.
Founder, Chairman, Chief Executive Officer and President
Vice President of Finance and Controller
Senior Vice President of Regulatory Policy and Counsel
Vice President of Human Resources
Compensation as of Fiscal Year 2016.
Putney, Inc. Key Developments
Dechra Pharmaceuticals plc, Putney, Inc. - M&A Call
Mar 15 16
To discuss the acquisition and placing
Putney, Inc. Launches Tiletamine-Zolazepam, First-To-Market Generic of Telazol
Jun 17 15
Putney, Inc. announced that its Tiletamine-Zolazepam (tiletamine HCl and zolazepam HCl) injectable, the only FDA-approved generic of Zoetis’ Telazol, is now commercially available. Veterinarians can purchase the drug through one of Putney’s network of regional distributors or directly from Putney. National veterinary distributors are prevented from carrying Putney’s Tiletamine-Zolazepam by “exclusive dealing agreements”, so-called in the recent FTC report entitled “Competition in the Pet Medications Industry.
Putney, Inc. Launches Putney Carprofen Chewable Tablets
Dec 18 14
Putney, Inc. announced that it is launching Putney Carprofen Chewable Tablets, its FDA approved generic of Zoetis’ popular Rimadyl® Chewable Tablets. With this product approval, the company’s fourth in less than three months, Putney is the company with FDA approved generics of all three dosage forms of carprofen products – Putney Carprofen Chewable Tablets, Putney Carprofen Sterile Injectable Solution, and Putney Carprofen Caplets. Putney’s other recent FDA approvals include Putney Dexmedetomidine HCl, a first-to-market generic of Dexdomitor® and the company’s third approval of a first-to-market generic in less than two years. Putney expects to penetrate and expand the $70 million carprofen chewable tablet market rapidly as veterinarians opt to save approximately 30% on Putney’s bioequivalent product (compared to Rimadyl® Chewable Tablets current list price).
Similar Private Companies By Industry
Recent Private Companies Transactions
March 15, 2016
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries